EGFR and diabetes mellitus: While neratinib is not at all selective for MST1, we believe that the underlying mechanisms of diabetes protection still derive from a direct protective effect on the β-cell mediated by MST1 and not from an effect on insulin sensitivity mediated by EGFR.